Ovex (p,p'-dichlorodiphenyltrichloroethane, DDT) is a synthetic organic compound that was widely used as an insecticide in the mid-20th century. It was highly effective in controlling mosquitoes and other insects that spread diseases such as malaria and typhus. However, due to its persistence in the environment and its potential to accumulate in the food chain, ovex was banned in many countries. Ovex was synthesized in the 1930s and its insecticidal properties were discovered shortly after. It works by disrupting the nervous system of insects, causing paralysis and death. Its effectiveness in controlling insect populations led to its widespread use in agriculture and public health. Studies on ovex focus on its environmental impact, its persistence in the environment, its potential to bioaccumulate in food chains, and its long-term effects on human health. Ovex is still studied today to understand its potential for use in controlling specific insect populations that are resistant to other insecticides.'
ovex: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6635 |
| CHEMBL ID | 499017 |
| CHEBI ID | 82155 |
| SCHEMBL ID | 116752 |
| MeSH ID | M0046730 |
| Synonym |
|---|
| lethalaire g-58 |
| miticide k-101 |
| ephirsulphonate |
| trichlorfenson |
| pcpcbs |
| CCS , |
| 80-33-1 |
| 4-chlorobenzenesulfonate de 4-chlorophenyle |
| chlorfensonchlorofensone |
| ester sulfonate |
| wln: gr dswor dg |
| (4-chloor-fenyl)-4-chloor-benzeen-sulfonaat |
| nsc-5618 |
| chlorfenson |
| 4-chlorophenyl 4-chlorobenzenesulfonate |
| (4-chlor-phenyl)-4-chlor-benzol-sulfonate |
| cpcbs |
| orthotran |
| nsc5618 |
| chlorobenzolsulfonate |
| p-chlorophenyl p-chlorobenzenesulfonate |
| onex |
| genite 883 |
| erysit |
| sappilan |
| ovatran |
| otracid |
| mitran |
| ovotox |
| sappiran |
| difenson |
| chloorfenson |
| acaricydol e 20 |
| (4-cloro-fenil)-4-cloro-venzol-solfonato |
| benzolsulfonate |
| orochlor |
| ovex |
| c 1,006 |
| ovatron |
| k 6451 |
| estonmite |
| chlorfensin |
| d 854 |
| p-chlorobenzenesulfonic acid, p-chlorophenyl ester |
| ovochlor |
| ovotran |
| chlorofenizon |
| ethersulfonate |
| niagaratran |
| corotran |
| ent 16,358 |
| c-854 |
| benzenesulfonic acid, 4-chloro-, 4-chlorophenyl ester |
| (4-chlorophenyl) 4-chlorobenzenesulfonate |
| benzenesulfonic acid, p-chloro-, p-chlorophenylester |
| p-chlorophenyl-p-chlorobenzene sulfonate |
| danicut |
| 4-chlorobenzenesulfonate de 4-chlorophenyle [french] |
| 4-chlorphenyl-4'-chlorbenzolsulfonat [german] |
| epa pesticide chemical code 020201 |
| chlorfenson [bsi:iso] |
| caswell no. 624 |
| 4-chlorophenyl 4-chlorobenzenesulphonate |
| chlorofensone |
| chlorefenizon [french] |
| trichlorfenson (obs.) |
| chlorofenson |
| p-chlorfenylester kyseliny p-chlorbenzensulfonove [czech] |
| 4-chlorobenzenesulfonate de 4-chlorphenyle [french] |
| ent 16,538 |
| hsdb 2055 |
| benzenesulfonic acid, p-chloro-, p-chlorophenyl ester |
| nsc 5618 |
| k-101 |
| chloorfenson [dutch] |
| brn 2944674 |
| p-chlorophenyl p-chlorobenzenesulphonate |
| dow k-6,451 |
| ovex [ansi] |
| einecs 201-270-4 |
| (4-chloor-fenyl)-4-chloor-benzeen-sulfonaat [dutch] |
| (4-chlor-phenyl)-4-chlor-benzol-sulfonate [german] |
| 4-chlorobenzenesulfonic acid, 4-chlorophenyl ester |
| ai3-16538 |
| benzolsulfonat |
| chlorbenzolsulfonat |
| (4-cloro-fenil)-4-cloro-venzol-solfonato [italian] |
| parachlorophenyl parachlorobenzene sulfonate |
| parachlorophenyl-parachlorobenzene-sulfonate |
| CHEMBL499017 |
| chebi:82155 , |
| rzxlpprpeouenn-uhfffaoysa- |
| inchi=1/c12h8cl2o3s/c13-9-1-5-11(6-2-9)17-18(15,16)12-7-3-10(14)4-8-12/h1-8h |
| NCGC00249010-01 |
| C19024 |
| NCGC00256598-01 |
| cas-80-33-1 |
| dtxsid5020310 , |
| dtxcid50310 |
| tox21_302742 |
| tox21_201263 |
| NCGC00258815-01 |
| 4-11-00-00109 (beilstein handbook reference) |
| chlorefenizon |
| lw65nj3ywv , |
| unii-lw65nj3ywv |
| p-chlorfenylester kyseliny p-chlorbenzensulfonove |
| 4-chlorobenzenesulfonate de 4-chlorphenyle |
| 4-chlorphenyl-4'-chlorbenzolsulfonat |
| ovex [inci] |
| chlorfenson [iso] |
| chlorfenson [mi] |
| chlorfenson [hsdb] |
| DB05377 |
| SCHEMBL116752 |
| 4-chlorophenyl-4-chlorobenzene sulfonate |
| RZXLPPRPEOUENN-UHFFFAOYSA-N |
| AKOS028110676 |
| chlorfenson, pestanal(r), analytical standard |
| Q2964122 |
| Class | Description |
|---|---|
| arenesulfonic acid | Organic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.3365 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 35.2532 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743063 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 51.3019 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 17.3430 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 10.2741 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 13.3816 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 51.3170 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259401 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 42.9208 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.7922 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 61.4003 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 37.7696 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1259385 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.0014 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 34.6654 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.3060 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 61.9396 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 61.1306 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID390724 | Inhibition of HSL in Wistar rat isolated fat cells at 10 uM by spectrophotometric assay | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (46.30) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||